US Edition
Published • loading... • Updated
AAN 2026: Crexont linked to more on time in new Parkinson’s study
Summary by Parkinson's News Today
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
AAN 2026: Crexont linked to more on time in new Parkinson’s study
People with Parkinson’s disease who switch from other formulations of levodopa to Crexont may experience improvements in daily symptom control, according to new data from an ongoing clinical trial. “Crexont substantially increased [good on] time, reduced [off time], and improved motor function in [Parkinson’s] patients across all therapy groups, confirming that switching patients from other levodopa-based therapies to Crexont offers meaningful i…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
